产品
编 号：F239741
分子式：C26H29N5O7
分子量：523.54
分子式：C26H29N5O7
分子量：523.54
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 192755-52-5
产品详情
生物活性：
Pralnacasan (VX-740) is a potent, selective, non-peptide and orally active interleukin-1β converting enzyme (ICE, caspase 1) inhibitor with a Ki of 1.4 nM. Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment.
体内研究：
Pralnacasan (0 -50 mg/kg; oral gavage; twice a day; for 6 weeks; female Balb/c mice) treatment reduces joint damage. Pralnacasan treatment does not appear to affect the weight of the animals.Animal Model:Female Balb/c mice induced with collagenase
Dosage:0 mg/kg, 12.5 mg/kg, 25 mg/kg and 50 mg/kg
Administration:Oral gavage; twice a day; for 6 weeks
Result:Significantly ameliorated the histopathological damage of the medial knee joint compartments.
Pralnacasan (VX-740) is a potent, selective, non-peptide and orally active interleukin-1β converting enzyme (ICE, caspase 1) inhibitor with a Ki of 1.4 nM. Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment.
体内研究：
Pralnacasan (0 -50 mg/kg; oral gavage; twice a day; for 6 weeks; female Balb/c mice) treatment reduces joint damage. Pralnacasan treatment does not appear to affect the weight of the animals.Animal Model:Female Balb/c mice induced with collagenase
Dosage:0 mg/kg, 12.5 mg/kg, 25 mg/kg and 50 mg/kg
Administration:Oral gavage; twice a day; for 6 weeks
Result:Significantly ameliorated the histopathological damage of the medial knee joint compartments.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备